✨ Free AI Report
OmniAb, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research OmniAb, Inc.
Company Research

OmniAb, Inc.: Business Overview, Financials & Competitive Analysis

OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable therapeutics discovery. The company's platform creates and screens diverse antibody repertoires...

Analyst-debate audio for OmniAb, Inc.

AskCyborg analysts argue the bull and bear cases for OmniAb, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Transformative OmniUltra platform launch and expanding partner ecosystem position OmniAb for milestone acceleration, but...

Read the full analyst-debate transcript →
Industry Biotechnology - Antibody & Protein Discovery Platforms
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest OmniAb, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

OmniAb, Inc. Overview

Pro stress-test →

OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable therapeutics discovery. The company's platform creates and screens diverse antibody repertoires to identify optimal antibodies and target-binding proteins for partners' drug development efforts.

Strategic Profile

Pro stress-test →

OmniAb's Biological Intelligence platform powers transgenic animal immune systems to create optimized antibody candidates, including proprietary technologies like OmniRat, OmniChicken, OmniMouse, and the newly launched OmniUltra platform. The company operates with 104 active partners, 399 active programs and 32 programs in clinical development or commercialization.

Competitive Landscape

Pro stress-test →

OmniAb faces growing competition from alternative antibody discovery and AI-driven platforms that may require higher R&D spending, risking long-term profitability and market share erosion. Key competitors include Genentech/Roche, Regeneron, and emerging AI-powered discovery platforms. OmniAb differentiates through proprietary transgenic animal technologies and expanding AI integration.

Industry Context

OmniAb, Inc. operates in Biotechnology - Antibody & Protein Discovery Platforms.

Key facts

Founded: 2012 · Headquarters: Emeryville, California · Revenue: $18-22M (2025E) · Market cap: $246M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on OmniAb, Inc..

  • OmniUltra launched December 2025 - transgenic chicken generating human immune repertoires with ultralong CDRH3 domains enabling antibodies and peptide therapeutics for bispecifics, CAR-T, and radioligands.
  • Q3 2025 revenue $2.2M YoY decline with 9-month revenue $10.3M and $50.6M operating loss, indicating challenging near-term economics.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Launched OmniUltra transgenic chicken platform with ultralong CDRH3 domains
  • November 2025Reported Q3 results with $2.2M revenue and $16.5M net loss; guided 2025 revenue $18-22M
  • +2 moreTrack every material event for OmniAb, Inc. as it happens. Explore monitoring →
Get alerted when OmniAb, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Antibody Discovery PlatformsIntegrated pharma with internal antibody discovery capabilities→VelociMouse TechnologyCompeting transgenic mouse platform for antibody discovery→AI-Driven DiscoveryAI and machine learning-based therapeutic discovery→

Compare OmniAb, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

OmniAb, Inc. operates in Biotechnology - Antibody & Protein Discovery Platforms. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Antibody & Protein Discovery Platforms research →
NEW · MCP server

Ask your AI assistant about OmniAb, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare OmniAb, Inc. and its top competitor on Cyborg Score”
“What did OmniAb, Inc. do this quarter?”
“Is OmniAb, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does OmniAb, Inc. do?+
OmniAb licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable therapeutics discovery. The company's platform creates and screens diverse antibody repertoires...
What is OmniAb, Inc.'s Cyborg Score?+
OmniAb, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are OmniAb, Inc.'s main competitors?+
Named competitors include Antibody Discovery Platforms, VelociMouse Technology, AI-Driven Discovery. The full competitive landscape is in the AskCyborg report.
How can I get the full OmniAb, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the OmniAb, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track OmniAb, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.